How Full-Life Technologies is using US$150m to push beyond platform promise
Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.
Why Norgine’s PEDMARQSI approval in Switzerland could reshape cisplatin ototoxicity management
Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.
OverT Bio moves OVT-101 closer to clinic as solid tumour cell therapy race intensifies
OverT Bio is advancing OVT-101 toward the clinic in ovarian cancer. Read what its new advisory board could change for solid tumour cell therapy.